Patritumab deruxtecan

Patritumab deruxtecan (HER3-DXd) is an antibody-drug conjugate (ADC) consisting of a fully human anti-HER3 IgG1 monoclonal antibody Patritumab (HY-P99275) attached to a topoisomerase I inhibitor (a toxin component of Dxd) payload via a tetrapeptide-based cleavable linker. Patritumab deruxtecan shows anticancer activity. This product is for research use only. Patritumab deruxtecan has an approximate molecular weight of 158 kDa. The DAR is n = ~3.4. Mirvetuximab soravtansine has an anti-proliferative effect via growth arrest and augmented DNA damage. This product is for research use only.

Product Details
Species Reactivity	Human
Type	Antibody-drug conjugate
ADC antibody	Patritumab (anti-HER3)
ADC cytotoxin (drug)	Dxd
Immunogen	Human HER3
DAR (Drug to Antibody Ratio)	~8
Purity	91%
Molecular Weight	158kDa
Protein Concentration	10mg/ml
Storage Condition	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.
Storage Buffer	PBS buffer pH7.4